Case report: Refractory autoimmune hemolytic anemia treated with rituximab
Main Article Content
Abstract
We report the initial treatment outcomes of six patients with refractory autoimmune hemolytic anemia (AIHA) who received rituximab at the National Institute of Hematology and Blood Transfusion between 2023 and 2024. The median follow-up duration was 13.9 months. The overall response rate was 66.7%, including complete response in 50% and partial response in 16.7% of patients. Hemoglobin levels improved significantly, transfusion requirements were reduced, and treatment was generally well tolerated with minimal adverse effects. Rituximab may be considered a promising therapeutic option for refractory AIHA; however, larger studies with longer follow-up are needed to confirm its efficacy in the Vietnamese population.
Article Details
Keywords
Refractory autoimmune hemolytic anemia, AIHA
References
2. Hill QA, Stamps R, Massey E, et al. Guidelines on the management of autoimmune hemolytic anemia. Br J Haematol. 2017;176(3):395-411.
3. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936. doi:10.1182/blood-2014-06-583134
4. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648
5. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857-3861. doi:10.1182/blood-2002-09-2731
6. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood. 2020;135(14):1066-1074. doi:10.1182/blood.2019003743
7. Gafter-Gvili A, Fraser A, Paul M, et al. Rituximab and the risk of infection: a systematic review and meta-analysis. PLoS One. 2013;8(4):e71335.
8. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học: thiếu máu tan máu tự miễn. Nhà xuất bản Y học; 2022:49-54.
9. McDevitt PW, Fichtner R, Frame JN. Rituximab (R) for the treatment of autoimmune hemolytic anemia (AIHA) in adults: an analysis of literature reports in 92 patients. Blood. 2004;104(11):3721. doi:10.1182/blood.V104.11.3721.3721
10. Waldron C, Ito S, Wang D, et al. Second-line therapy sequencing in primary warm autoimmune hemolytic anemia: splenectomy-rituximab versus rituximab-splenectomy. Blood. 2023;142(suppl 1):2317. doi:10.1182/blood-2023-189957
11. Lê KQ, Nguyễn QT. Nghiên cứu một số đặc điểm lâm sàng, xét nghiệm ở bệnh nhân tan máu tự miễn tại Viện Huyết học - Truyền máu Trung ương. Tạp chí Y Dược học. 2021;(35):24-28.